A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Non-small Cell Lung Cancer
DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Cisplatin
Overall survival (OS) in randomized participants with PD-L1 1% to 49%, Up to 5 years
OS in randomized participants with PD-L1 ≥ 1%, Up to 5 years|Progression-free survival (PFS) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR), Up to 5 years|Overall response rate (ORR), Up to 5 years|Duration of response (DoR), Up to 5 years|Number of participants with adverse events (AEs), Up to 2.5 years|Number of participants with serious adverse events (SAEs), Up to 2.5 years|Number of participants with immune-mediated adverse events (IMAEs), Up to 2.5 years|The time until definitive deterioration based on non-small cell lung cancer - symptom assessment questionnaire (NSCLC-SAQ) total score, Up to 2 years
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%